By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan - 2Building an Individual Brand: Illustrations from Forces to be reckoned with
- 321 Things You Ought to Never Share with Your Childless Companion
- 4Great DSLR Cameras for Photography Devotees
- 55 Movies That Leaving an Imprint with Inventive Innovation
- Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- Manual for Savvy Home Lighting Framework: Lights up Your Space
- Why won't NASA's Artemis 2 astronauts land on the moon when they get there?
- RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- Financial plan Cordial Home Redesigns That Add Worth
- 'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Moving Pool Highlights for 2024
